Auto logout in seconds.
Continue LogoutDiagnostic testing is changing as new technologies create opportunities to bring testing closer to patients, detect a wider range of pathogens, and use AI to help guide care. With respiratory virus season underway, a look at testing for flu, RSV, and COVID-19 offers a window into how these broader trends are shaping patient care.
Mayo Clinic Laboratories is seeing many of these shifts in diagnostic testing firsthand as it develops new testing approaches and explores how emerging technologies can improve access to and use of diagnostics. In “What 2026 revealed about the future of diagnostics,” President and CEO William Morice II, MD, PhD, examines broader shifts in advanced testing, access, and AI. And in a recent episode of Mayo Clinic Laboratories’ Answers From the Lab podcast, Chief Scientific Officer Matthew Binnicker, PhD, explores how emerging technologies could specifically change respiratory virus detection.
Here are three shifts that could change how and where patients are tested.
Respiratory virus testing already spans several settings. At-home antigen tests offer one option for screening, while PCR tests can test for influenza, RSV, and COVID-19. Rapid point-of-care testing is also available in settings such as urgent care clinics.
The next shift could bring more sophisticated testing into patients’ homes. Patients may increasingly be able to collect samples at home and send them to a laboratory for analysis, with more options for performing lab-quality tests at home emerging over time.
At-home testing is only one part of a broader shift toward making diagnostics more accessible. More advanced tests may remain in clinical settings, but point-of-care and other decentralized models could bring sophisticated diagnostic capabilities closer to patients. That access will become increasingly important as personalized medicine, genetic testing, and emerging therapies reshape care.
"Things will move closer and closer to the patient, meaning you may be able to collect a sample at home and have it sent in to the laboratory."
Most respiratory tests are designed to look for a predefined virus or group of viruses. PCR tests, for example, can simultaneously test for influenza, RSV, and COVID-19. But emerging technologies could eventually allow laboratories to search much more broadly, particularly when patients have severe or complex illnesses.
One technology to watch is metagenomic sequencing. Rather than looking for two or three predetermined viruses, the approach could allow laboratories to analyze a patient sample for any virus or other pathogen present. The technology likely won't be necessary for common respiratory illnesses. But in the next five to 10 years, Binnicker expects metagenomic sequencing could become more common in severe cases, including for patients who require hospitalization.
The development of these tests reflects a broader shift toward diagnostics that provide deeper clinical insights. Laboratory testing has long been essential to identifying and classifying disease, but newer approaches are expanding what laboratories can detect and could give clinicians more information when conventional testing doesn't provide a clear answer.
AI is also moving toward more practical applications in diagnostics.
Early research has combined information such as a patient's symptoms, age, temperature, and even an image of the throat to estimate the likelihood of one infectious agent versus another. While these applications remain at the proof-of-concept stage, they point to the potential for AI to support screening and help patients and clinicians determine what testing or therapies may be necessary.
But AI's role in diagnostics isn't limited to tools that clinicians working directly with patients are using to support their work. Inside the laboratory, AI is also being applied to the operational work that supports diagnostic testing. Mayo Clinic Laboratories is using AI-assisted specimen intake and triage to help reduce manual data entry and streamline workflows while keeping laboratory staff responsible for verification and final decisions. Teams have also explored using AI to support analyses and assist with drafting interpretive reports.
As these applications advance, AI could help laboratories manage growing volumes of data and give experts more time to focus on high-value clinical and scientific work that advances patient care.
"Much of the data fueling these innovations originates from diagnostic testing, meaning laboratorians will be essential going forward to ensure that data-driven tools are clinically meaningful and ethically sound to support better patient outcomes."
Even as diagnostic capabilities expand, more testing won't necessarily be appropriate for every patient. Many people with mild to moderate respiratory illnesses may not need testing, while it can become more important as illness grows more severe or when patients, or those they live with, have underlying conditions that increase their risk.
The bigger shift is in what happens when testing is needed. Emerging approaches could make advanced diagnostics easier to access, broaden what laboratories can detect, and give clinicians more information to guide the next step in care.
Read the full Mayo Clinic Laboratories article and listen to podcast episode to learn more about the trends and technologies shaping diagnostic testing.
Mayo Clinic Laboratories provides specialized laboratory testing for serious and complex conditions to advance patient care worldwide. For 55 years, Mayo Clinic Laboratories has helped physicians answer the toughest clinical questions with confidence and empowered hospitals to elevate care within their communities. Through an integrated diagnostics ecosystem powered by Mayo Clinic, the organization offers access to more than 4,000 tests and pathology services, delivering trusted, timely answers to clinicians and patients. Learn more here.
This report is sponsored by Mayo Clinic Laboratories, an Advisory Board member organization. Representatives of Mayo Clinic Laboratories helped select the topics and issues addressed. Advisory Board experts wrote the report, maintained final editorial approval, and conducted the underlying research independently and objectively. Advisory Board does not endorse any company, organization, product or brand mentioned herein.
To learn more, view our editorial guidelines.
This expert insight is sponsored by Mayo Clinic Laboratories. Advisory Board experts wrote the article, maintained final editorial approval, and conducted the underlying research independently and objectively.
Create your free account to access 1 resource, including the latest research and webinars.
You have 1 free members-only resource remaining this month.
1 free members-only resources remaining
1 free members-only resources remaining
You've reached your limit of free insights
Never miss out on the latest innovative health care content tailored to you.
You've reached your limit of free insights
Never miss out on the latest innovative health care content tailored to you.
This content is available through your Curated Research partnership with Advisory Board. Click on ‘view this resource’ to read the full piece
Email ask@advisory.com to learn more
Never miss out on the latest innovative health care content tailored to you.
This is for members only. Learn more.
Never miss out on the latest innovative health care content tailored to you.